183 related articles for article (PubMed ID: 37604642)
1. T-cell receptor beta variable gene polymorphism predicts immune-related adverse events during checkpoint blockade immunotherapy.
Stephen B; Hajjar J; Sarda S; Duose DY; Conroy JM; Morrison C; Alshawa A; Xu M; Zarifa A; Patel SP; Yuan Y; Kwiatkowski E; Wang L; Rodon Ahnert J; Fu S; Meric-Bernstam F; Lowman GM; Looney T; Naing A
J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37604642
[TBL] [Abstract][Full Text] [Related]
2. The determinants of very severe immune-related adverse events associated with immune checkpoint inhibitors: A prospective study of the French REISAMIC registry.
Ruste V; Goldschmidt V; Laparra A; Messayke S; Danlos FX; Romano-Martin P; Champiat S; Voisin AL; Baldini C; Massard C; Laghouati S; Marabelle A; Lambotte O; Michot JM
Eur J Cancer; 2021 Nov; 158():217-224. PubMed ID: 34627664
[TBL] [Abstract][Full Text] [Related]
3. The Inconsistent and Inadequate Reporting Of Immune-Related Adverse Events in PD-1/PD-L1 Inhibitors: A Systematic Review of Randomized Controlled Clinical Trials.
Xie T; Zhang Z; Qi C; Lu M; Zhang X; Li J; Shen L; Peng Z
Oncologist; 2021 Dec; 26(12):e2239-e2246. PubMed ID: 34396642
[TBL] [Abstract][Full Text] [Related]
4. A Review of Cancer Immunotherapy Toxicity: Immune Checkpoint Inhibitors.
Chhabra N; Kennedy J
J Med Toxicol; 2021 Oct; 17(4):411-424. PubMed ID: 33826117
[TBL] [Abstract][Full Text] [Related]
5. A Potential Mechanism of Anticancer Immune Response Coincident With Immune-related Adverse Events in Patients With Renal Cell Carcinoma.
Kato T; Tomiyama E; Koh Y; Matsushita M; Hayashi Y; Nakano K; Ishizuya YU; Wang C; Hatano K; Kawashima A; Ujike T; Kawasaki K; Morii E; Gotoh K; Eguchi H; Kiyotani K; Fujita K; Nonomura N; Uemura M
Anticancer Res; 2020 Sep; 40(9):4875-4883. PubMed ID: 32878775
[TBL] [Abstract][Full Text] [Related]
6. Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe gastrointestinal and hepatic toxicities from checkpoint inhibitors.
Dougan M; Blidner AG; Choi J; Cooksley T; Glezerman I; Ginex P; Girotra M; Gupta D; Johnson D; Shannon VR; Suarez-Almazor M; Anderson R; Rapoport BL
Support Care Cancer; 2020 Dec; 28(12):6129-6143. PubMed ID: 32856210
[TBL] [Abstract][Full Text] [Related]
7. Immunogenetic variations predict immune-related adverse events for PD-1/PD-L1 inhibitors.
Xin Z; You L; Na F; Li J; Chen M; Song J; Bai L; Chen J; Zhou J; Ying B
Eur J Cancer; 2023 May; 184():124-136. PubMed ID: 36917924
[TBL] [Abstract][Full Text] [Related]
8. Investigational Biomarkers for Checkpoint Inhibitor Immune-Related Adverse Event Prediction and Diagnosis.
von Itzstein MS; Khan S; Gerber DE
Clin Chem; 2020 Jun; 66(6):779-793. PubMed ID: 32363387
[TBL] [Abstract][Full Text] [Related]
9. Gut microbiome for predicting immune checkpoint blockade-associated adverse events.
Hu M; Lin X; Sun T; Shao X; Huang X; Du W; Guo M; Zhu X; Zhou Y; Tong T; Guo F; Han T; Wu X; Shi Y; Xiao X; Zhang Y; Hong J; Chen H
Genome Med; 2024 Jan; 16(1):16. PubMed ID: 38243343
[TBL] [Abstract][Full Text] [Related]
10. Durable responses in patients with genitourinary cancers following immune checkpoint therapy rechallenge after moderate-to-severe immune-related adverse events.
Siddiqui BA; Gheeya JS; Goswamy R; Bathala TK; Surasi DS; Gao J; Shah A; Campbell MT; Msaouel P; Goswami S; Wang J; Zurita AJ; Jonasch E; Corn PG; Aparicio AM; Siefker-Radtke AO; Sharma P; Subudhi SK; Tannir N
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34326169
[TBL] [Abstract][Full Text] [Related]
11. Prediction of severe immune-related adverse events requiring hospital admission in patients on immune checkpoint inhibitors: study of a population level insurance claims database from the USA.
Kalinich M; Murphy W; Wongvibulsin S; Pahalyants V; Yu KH; Lu C; Wang F; Zubiri L; Naranbhai V; Gusev A; Kwatra SG; Reynolds KL; Semenov YR
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33789879
[TBL] [Abstract][Full Text] [Related]
12. Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study.
Cortellini A; Buti S; Santini D; Perrone F; Giusti R; Tiseo M; Bersanelli M; Michiara M; Grassadonia A; Brocco D; Tinari N; De Tursi M; Zoratto F; Veltri E; Marconcini R; Malorgio F; Garufi C; Russano M; Anesi C; Zeppola T; Filetti M; Marchetti P; Botticelli A; Antonini Cappellini GC; De Galitiis F; Vitale MG; Sabbatini R; Bracarda S; Berardi R; Rinaldi S; Tudini M; Silva RR; Pireddu A; Atzori F; Chiari R; Ricciuti B; Iacono D; Migliorino MR; Rossi A; Porzio G; Cannita K; Ciciarelli V; Fargnoli MC; Ascierto PA; Ficorella C
Oncologist; 2019 Jun; 24(6):e327-e337. PubMed ID: 30796151
[TBL] [Abstract][Full Text] [Related]
13. Safety of immune checkpoint inhibitor rechallenge after discontinuation for grade ≥2 immune-related adverse events in patients with cancer.
Allouchery M; Lombard T; Martin M; Rouby F; Sassier M; Bertin C; Atzenhoffer M; Miremont-Salame G; Perault-Pochat MC; Puyade M;
J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33428586
[TBL] [Abstract][Full Text] [Related]
14. Regulatory T-cell Transcriptomic Reprogramming Characterizes Adverse Events by Checkpoint Inhibitors in Solid Tumors.
Grigoriou M; Banos A; Hatzioannou A; Kloetgen A; Kouzis P; Aggouraki D; Zakopoulou R; Bamias G; Kassi E; Mavroudis D; Bamias A; Boumpas DT; Tsirigos A; Gogas H; Alissafi T; Verginis P
Cancer Immunol Res; 2021 Jul; 9(7):726-734. PubMed ID: 33820810
[TBL] [Abstract][Full Text] [Related]
15. Prospective evaluation of the prognostic value of immune-related adverse events in patients with non-melanoma solid tumour treated with PD-1/PD-L1 inhibitors alone and in combination with radiotherapy.
Schweizer C; Schubert P; Rutzner S; Eckstein M; Haderlein M; Lettmaier S; Semrau S; Gostian AO; Frey B; Gaipl US; Zhou JG; Fietkau R; Hecht M
Eur J Cancer; 2020 Nov; 140():55-62. PubMed ID: 33045663
[TBL] [Abstract][Full Text] [Related]
16. Peripheral Blood Markers Identify Risk of Immune-Related Toxicity in Advanced Non-Small Cell Lung Cancer Treated with Immune-Checkpoint Inhibitors.
Pavan A; Calvetti L; Dal Maso A; Attili I; Del Bianco P; Pasello G; Guarneri V; Aprile G; Conte P; Bonanno L
Oncologist; 2019 Aug; 24(8):1128-1136. PubMed ID: 31015312
[TBL] [Abstract][Full Text] [Related]
17. Supportive care for patients undergoing immunotherapy.
Rapoport BL; van Eeden R; Sibaud V; Epstein JB; Klastersky J; Aapro M; Moodley D
Support Care Cancer; 2017 Oct; 25(10):3017-3030. PubMed ID: 28707167
[TBL] [Abstract][Full Text] [Related]
18. Late-onset and long-lasting immune-related adverse events from immune checkpoint-inhibitors: An overlooked aspect in immunotherapy.
Ghisoni E; Wicky A; Bouchaab H; Imbimbo M; Delyon J; Gautron Moura B; Gérard CL; Latifyan S; Özdemir BC; Caikovski M; Pradervand S; Tavazzi E; Gatta R; Marandino L; Valabrega G; Aglietta M; Obeid M; Homicsko K; Mederos Alfonso NN; Zimmermann S; Coukos G; Peters S; Cuendet MA; Di Maio M; Michielin O
Eur J Cancer; 2021 May; 149():153-164. PubMed ID: 33865201
[TBL] [Abstract][Full Text] [Related]
19. T-cell tolerant fraction as a predictor of immune-related adverse events.
Ostmeyer J; Park JY; von Itzstein MS; Hsiehchen D; Fattah F; Gwin M; Catalan R; Khan S; Raj P; Wakeland EK; Xie Y; Gerber DE
J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37580069
[TBL] [Abstract][Full Text] [Related]
20. Checkpoint-blocker-induced autoimmunity is associated with favourable outcome in metastatic melanoma and distinct T-cell expression profiles.
Ye W; Olsson-Brown A; Watson RA; Cheung VTF; Morgan RD; Nassiri I; Cooper R; Taylor CA; Akbani U; Brain O; Matin RN; Coupe N; Middleton MR; Coles M; Sacco JJ; Payne MJ; Fairfax BP
Br J Cancer; 2021 May; 124(10):1661-1669. PubMed ID: 33723392
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]